Join us February 13, 2025, from 12-2 pm Eastern Time for the Illuminate Hypersomnia Adjunct Scientific Meeting. This virtual scientific session aims to address critical challenges in drug development for idiopathic hypersomnia (IH), as identified during the groundbreaking Illuminate Hypersomnia Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting held on April 11, 2024.
The Illuminate Hypersomnia Adjunct Scientific Meeting will bring together experts in the fields of sleep medicine, pharmaceutical research, regulatory science, medical affairs, and patient advocacy. The focus will be on collaborative efforts to overcome key scientific and drug development hurdles in the development of effective treatments for idiopathic hypersomnia. Read Sleep Consortium’s press release announcing this event.
"*" indicates required fields
Welcome & Introductions
Sleep Consortium
Kim McCleary, Kith Collective
Recap of Illuminate Hypersomnia EL-PFDD
Lynn Marie Trotti, MD, MSc
Topic #1 Presentation: Brain Fog
Michael Thorpy, MB, ChB
Topic #1 Panel Discussion: Approaches to Better Defining and Measuring Brain Fog in IH
Kim McCleary (Moderator)
Lucie Barateau, MD, PhD
Kiran Maski, MD, MPH
Anne Marie Morse, DO
David Plante, MD, PhD
Topic #2 Presentation: Barriers to Participation in Research Studies
Emmanuel Mignot, MD, PhD
Topic #2 Panel Discussion: Considerations for Recruiting and Retaining People with IH in Research Studies
Kim McCleary (Moderator)
Omavi Bailey, MD, MPH
Yves Dauvilliers, MD, PhD
Additional panelists TBC
Industry Roundtable: Discussion of Unmet Needs for IH Identified by the Illuminate Hypersomnia Initiative
Industry Representatives
Recap, Next Steps, and Closing Remarks
Sleep Consortium
Kim McCleary
Thank you to these generous sponsors for unrestricted educational grants in support of the Illuminate Hypersomnia Adjunct Scientific Meeting:
For questions or more information about the Illuminate Hypersomnia Adjunct Scientific Meeting, reach out to us via email at PFDD@sleepconsortium.org.